Fundamental Pharma

PharmatrophiX

The company develops small-molecule therapies targeting neurotrophin receptors for patients with Alzheimer's disease and other neurodegenerative disorders.

Cyclerion Therapeutics

This biopharmaceutical company develops neuropsychiatric therapies for patients with treatment-resistant depression and other neurodegenerative diseases.

Yumanity Therapeutics

This company develops small molecule drugs to treat neurodegenerative diseases for patients with conditions such as Parkinson's disease and amyotrophic lateral sclerosis.

Augustine Therapeutics

This company develops small molecule inhibitors to treat patients with neuromuscular, neurodegenerative and cardio-metabolic diseases.

CuraSen Therapeutics

This biopharmaceutical company develops small molecule drugs to treat patients with neurodegenerative disorders, such as Parkinson's and Alzheimer's disease.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Enemsa Pharma

This company develops small-molecule neuroprotective therapies and combination drugs to treat patients with rare neurodegenerative and cardiopulmonary diseases.

Autobahn Therapeutics

This company develops brain-penetrating small molecule therapies for patients with neuropsychiatric and neuroimmunologic disorders, including depression and multiple sclerosis.